<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824197</url>
  </required_header>
  <id_info>
    <org_study_id>18-446 MR 1901</org_study_id>
    <nct_id>NCT03824197</nct_id>
  </id_info>
  <brief_title>Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)</brief_title>
  <acronym>(AU-ROOAD)</acronym>
  <official_title>Extra-virgin Olive Oil Prevents Mild Cognitive Impairment Conversion to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auburn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auburn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Until now there is no medical treatment and/or intervention that can slow, stop or reverse
      the underlying neurodegenerative of Alzheimer's disease (AD). The goal of this study is to
      demonstrate &quot;Oleocanthal rich-extra-virgin olive oil (EVOO) consumption stops or delay mild
      cognitive impairment conversion to AD by restoring the blood-brain barrier (BBB) function in
      humans&quot;.

      Specific Aims:

        1. Evaluate effect of EVOO on the brain function by functional MRI (fMRI) imaging, and BBB
           function by dynamic contrast-enhanced MRI (DCE-MRI).

        2. Evaluate effect of EVOO on cognitive function and on selected biomarkers
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of olive oil on the BBB intactness</measure>
    <time_frame>6 months</time_frame>
    <description>Will be evaluated by DCE-MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of olive oil on the brain activity</measure>
    <time_frame>6 months</time_frame>
    <description>Will be evaluated by fMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>6 months</time_frame>
    <description>A battery of cognitive tasks to assess memory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cerebral Amyloid Angiopathy</condition>
  <arm_group>
    <arm_group_label>EVOO-phenol high</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OO-phenol low</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Olive oil with low phenolic content that will be added to daily diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EVOO</intervention_name>
    <description>Extra-virgin olive oil that is rich with oleocanthal and other phenols.</description>
    <arm_group_label>EVOO-phenol high</arm_group_label>
    <other_name>OC-rich EVOO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OO</intervention_name>
    <description>Olive oil low in oleocanthal and other phenols.</description>
    <arm_group_label>OO-phenol low</arm_group_label>
    <other_name>Olive oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women, experiencing mild cognitive impairment with:

          1. Mini-Mental State Exam (MMSE) scores between 18-30 (based on education level

          2. memory complaint, have objective memory loss measured by education adjusted scores on
             Wechsler Memory Scale Logical Memory VI

          3. Clinical Dementia Rating (CDR) score 0.5.

        Exclusion Criteria:

          1. Subjects with contradictions for MRI include: the presence of metal or electronic
             devices such as metallic joint prostheses, artificial heart valves, an implantable
             heart defibrillator, a pacemaker, metal clips, cochlear implants, a bullet, shrapnel
             or any other type of metal fragment; breathing problems or disorders, claustrophobia,
             inner ear disorders, vertigo or dizziness, tattoos or permanent makeup that contains
             metal, and body piercing jewelry that cannot be removed.

          2. Subjects will be excluded if they are smokers

          3. Subjects who have have clinically important medical or neuropsychiatric comorbidity.

          4. Subjects who have renal problems or are allergic to the MRI contrast agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amal Kaddoumi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auburn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auburn University</name>
      <address>
        <city>Auburn</city>
        <state>Alabama</state>
        <zip>36849</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Auburn University</investigator_affiliation>
    <investigator_full_name>Amal Kaddoumi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy</mesh_term>
    <mesh_term>Cerebral Amyloid Angiopathy, Familial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

